SPECIAL SERIES: INFORMATICS TOOLS FOR CANCER RESEARCH AND CARE

Electronic Medical Record Search Engine (EMERSE): An Information Retrieval Tool for Supporting Cancer Research

David A. Hanauer, MD, MS1; Jill S. Bamholtz-Sloan, PhD2-4; Mark F. Beno, MSM2,4; Guilherme Del Fioli, MD, PhD5; Eric B. Durbin, DrPH6,7; Oksana Gologorskaya, MS8; Daniel Harris, PhD9; Brett Harnett, MSIS9; Kensaku Kawamoto, MD, PhD, MHS5; Benjamin May, MS10; Eric Meeks, BS8; Emily Pfaff, MS11; Janie Weiss, BS10; and Kai Zheng, PhD12

abstract

PURPOSE The Electronic Medical Record Search Engine (EMERSE) is a software tool built to aid research spanning cohort discovery, population health, and data abstraction for clinical trials. EMERSE is now live at three academic medical centers, with additional sites currently working on implementation. In this report, we describe how EMERSE has been used to support cancer research based on a variety of metrics.

METHODS We identified peer-reviewed publications that used EMERSE through online searches as well as through direct e-mails to users based on audit logs. These logs were also used to summarize use at each of the three sites. Search terms for two of the sites were characterized using the natural language processing tool MetaMap to determine to which semantic types the terms could be mapped.

RESULTS We identified a total of 326 peer-reviewed publications that used EMERSE through August 2019, although this is likely an underestimation of the true total based on the use log analysis. Oncology-related research comprised nearly one third (n = 105; 32.2%) of all research output. The use logs showed that EMERSE had been used by multiple people at each site (nearly 3,500 across all three) who had collectively logged into the system 100,000 times. Many user-entered search queries could not be mapped to a semantic type, but the most common semantic type for terms that did match was “disease or syndrome,” followed by “Pharmacologic substance.”

CONCLUSION EMERSE has been shown to be a valuable tool for supporting cancer research. It has been successfully deployed at other sites, despite some implementation challenges unique to each deployment environment.

JCO Clin Cancer Inform 4:454-463. © 2020 by American Society of Clinical Oncology

LICENSED under the Creative Commons Attribution 4.0 License

INTRODUCTION

The vast volume of clinical data captured within electronic health records (EHRs) has the potential to catalyze biomedical research. However, for all the benefits of EHRs, persistent challenges remain in leveraging EHR data for cancer research. This is because a substantial number (up to 80% by some estimates)1 of the clinical details are captured in unstructured free-text notes and are therefore difficult to extract and convert to a computable form.2 Ignoring the free text in EHRs can be problematic.3 For example, symptomatic data are often recorded exclusively in the free text.4 One study found that free text from EHRs was required for resolving nearly 60% of eligibility criteria for a chronic lymphocytic leukemia clinical trial and almost 80% of eligibility criteria for a prostate cancer trial.5 Another such study listed 10 data elements derived from the free text related to bone marrow biopsy findings, including biopsy blast counts, biopsy cellularity, fibrosis grade, and aspirate cellularity.6 A study about engraftment syndrome after allogeneic hematopoietic cell transplantation used concepts found in the free text, such as engraftment failure, stool output, lymphocyte recovery, cytokine storm, disorientation, capillary leak, effusions, fevers, and rashes.7 Furthermore, the accuracy of the readily accessible structured data from EHRs may be low in some cases.8 For example, one study found that up to 20% of patients at one medical center had a medication listed in their unstructured data that was not in the structured medication list.9 Another study of cancer staging found that nearly 84% of patients had conflicting statements about staging in their records, necessitating an algorithm to infer the most likely staging for each patient.10 To help the research community use the free text in EHRs, substantial resources have been devoted to develop natural language processing (NLP) tools. NLP remains promising for oncology research,11 but

Author affiliations and support information (if applicable) appear at the end of this article. Accepted on February 27, 2020 and published at ascopubs.org/journal/jcci on May 15, 2020; doi: https://doi.org/10.1200/CCI.19.00134
An analysis of audit logs and peer-reviewed publications demonstrated that EMERSE is being used to support cancer research for a broad array of research projects and tasks, ranging from cohort identification to data abstraction for elements that may not be found in a structured form. Users are searching for a wide variety of concepts, including “pharmacologic substance,” “neoplasm,” “sign or symptom.”

Relevance

Information retrieval systems such as EMERSE have the potential to be powerful and easy-to-use software tools for supporting cancer research. EMERSE is available at no cost and has been successfully implemented at multiple medical centers, so it is a viable option for sites seeking to provide additional software tools for supporting cancer research.

CONTEXT

Key Objective

To demonstrate the utility of an information retrieval system, the Electronic Medical Record Search Engine (EMERSE), in the context of supporting cancer research.

Knowledge Generated

An analysis of audit logs and peer-reviewed publications demonstrated that EMERSE is being used to support cancer research for a broad array of research projects and tasks, ranging from cohort identification to data abstraction for elements that may not be found in a structured form. Users are searching for a wide variety of concepts, including “pharmacologic substance,” “neoplasm,” “sign or symptom.”

METHODS

System Description

EMERSE is a Web-based application that provides an easy-to-use interface for either (1) identifying a cohort among all patients in the EHR or identifying concepts within the clinical unstructured notes of an existing defined patient cohort. EMERSE indexes free-text data from EHR notes, with additional metadata related to the notes (eg, date, clinical service, note type). The software is based on Apache Solr (an open-source search engine), but a substantial user interface has been built to provide study management features, visualization of results, and a query expansion feature.

Technical details about EMERSE can be found in a prior publication. EMERSE maintains detailed audit logs for all user sessions. Figure 1 contains several screens from EMERSE showing various general functions of the system. A recently added feature visualizes trends over time based on the search terms of interest (Fig 2). Although EMERSE is intended to be a self-service tool, system support is expected to be managed centrally by groups such as operational informatics teams. EMERSE is available at no cost, including source code, but sites are required to contact the University of Michigan to obtain the software. Additional details about EMERSE, including documentation and explainer videos, can be found on the EMERSE project Web site.

EMERSE is currently in use at three academic medical centers: University of Michigan, University of North Carolina...
### Document:

**Journal:** Oncology case reports  
**Article Title:** Breast cancer: metastatic disease involving 
**Publication Date:** 2017-06-09

**Abstract:**
We report a case of mediastinal lymphadenopathy involving systemic metastatic disease involving the left parasternal lymph node. The patient was a 65-year-old woman with a history of breast cancer who presented with a large mass in the left parasternal region. The mass was found to be a metastatic lymph node, and the patient was treated with chemotherapy. The patient responded well to the treatment, and the mass diminished in size. The patient was monitored for signs of recurrence, and none were observed. The patient was discharged with a plan for follow-up at 3 months.

**Conclusion:** The patient responded well to chemotherapy, and the mass diminished in size. The patient was discharged with a plan for follow-up at 3 months.
at Chapel Hill, and University of Cincinnati (Table 1). Other sites are currently at various stages in their implementation, including Case Western Reserve University (CWRU)/University Hospitals of Cleveland, Columbia University, University of Kentucky, University of Utah, and University of California San Francisco. CWRU has implemented a version of EMERSE using data extracted from the MIMIC-III project and plans to use EMERSE in a pilot program for training medical students about research software and as part of its health informatics training program.

Publication Data

Peer-reviewed publications using EMERSE were identified via manual searches for “EMERSE” or “electronic medical record search engine” in both PubMed and Google Scholar. Searches were conducted between August and September 2019. Each article identified was reviewed to confirm EMERSE use. To identify additional peer-reviewed publications without mention or citation of EMERSE, all principal investigators at the University of Michigan who had used EMERSE for research within the prior 5-year period (n = 600) were sent an e-mail in July/August 2019 to inquire about the use of EMERSE for their work and what publications arose from that use. The e-mail contained personalized audit logs to remind them about the use. A follow-up e-mail to nonresponders was sent in early September 2019. For all articles identified, the titles and abstracts were read to determine if they were cancer related. To characterize how EMERSE was used to support various research initiatives, 47 recent cancer-related peer-reviewed publications published within the last 2 years were reviewed. Among these, 11 were summarized with respect to their descriptions of how EMERSE was used. These 11 articles were selected to showcase a diversity of use cases, were from a variety of research teams from different disciplines, and had enough details described in their methods sections to understand the contribution of EMERSE.

Audit Log Analysis

Use logs were extracted to characterize the total number of users and the number of EMERSE logins over the past 5 years (September 2014 through August 2019; shorter timeframes for the two sites that recently adopted the system). The search terms (ie, search queries) entered within this timeframe were also extracted. The NLP tool MetaMap was used to process the search terms from two of the sites (University of Michigan and University of Cincinnati; University of North Carolina did not provide its terms). For this analysis, the “-a -N” flags were used. The
“-a” flag enables the use of variants of acronyms and abbreviations, and the “-N” flag modifies how the output is displayed. Prior studies have shown that MetaMap can perform comparably to other NLP tools, such as cTAKES.

MetaMap processed each search term to determine if MetaMap could map the query to a concept unique identifier (CUI) within the Unified Medical Language System (UMLS) and, if the concept could be identified, to what semantic type it belonged. Because MetaMap outputs a list of potential CUI candidates, only the top-scoring candidate was selected. For ties among top-scoring candidates, only the first was selected. The results across the two sites were merged, and the relative frequencies of the top 20 most common UMLS semantic types were visualized using RAWGraphs.

RESULTS
A total of 222 peer-reviewed publications were identified through manual searches using PubMed and Google Scholar through September 19, 2019. For the e-mail survey that was conducted to gain additional data about publications, 337 (56.2%) of the 600 principal investigators responded, revealing an additional 105 peer-reviewed publications that did not cite or mention EMERSE, bringing the total number of publications to 326. Of the 326 publications, 105 (32.2%) were oncology related. An additional 285 studies were still in progress, with potential publications coming at a later date. The current list of known peer-reviewed publications can be found on the EMERSE project Web site. Summaries of how EMERSE was used for 11 selected oncology-related

| TABLE 1. Description of the Three Sites Currently Live With EMERSE |
|---------------------------------------------------------------|
| Institution | Go-Live Date | No. of Patients (millions) | No. of Documents (millions) | No. of Users | No. of Logins |
|-------------|--------------|---------------------------|-----------------------------|--------------|--------------|
| University of Michigan | Dec 2005 | 2.5 | 170 | 3,308<sup>a</sup> | 97,632<sup>a</sup> |
| University of North Carolina at Chapel Hill | Nov 2017 | 2.6 | 90 | 163<sup>b</sup> | 1,957<sup>b</sup> |
| University of Cincinnati | Feb 2019 | 0.9 | 27 | 24<sup>b</sup> | 550<sup>b</sup> |
| Overall | NA | 6.0 | 287 | 3,495 | 100,139 |

Abbreviations: EMERSE, Electronic Medical Record Search Engine; NA, not applicable.
<sup>a</sup>Last 5 years.
<sup>b</sup>Since go-live date.

| TABLE 2. Examples of Cancer-Related Publications Supported With Use of EMERSE |
|---------------------------------------------------------------|
| Publication | Description of EMERSE Use | Site of EMERSE Use |
|-------------|---------------------------|-------------------|
| Ernecoff<sup>25</sup> | To develop EHR phenotypes for identifying patients with late-stage solid tumor cancers | University of North Carolina at Chapel Hill |
| Zhang<sup>30</sup> | Case identification for patients with a malignant Brenner tumor (no specific ICD-10 code exists for this diagnosis) | University of North Carolina at Chapel Hill |
| Tsao<sup>31</sup> | Data abstraction for disease and treatment characteristics, performance status, and comorbid conditions (eg, hypertension, diabetes mellitus, congestive heart failure, cardiac arrhythmias) | University of Michigan |
| Siontis<sup>32</sup> | Cohort identification: identify patients with a diagnosis of primary cardiac sarcoma | University of Michigan |
| Lazo de la Vega<sup>33</sup> | Cohort identification: patients with low-grade endometrioid endometrial carcinoma, FIGO grade I/II at time of hysterectomy | University of Michigan |
| Shankar<sup>34</sup> | Case identification using lymph node pathology | University of Michigan |
| Hertz<sup>35</sup> | Screening for patients with actionable phenotypes to determine if they received a relevant drug, using generic and brand drug names | University of Michigan |
| Morag<sup>36</sup> | Cohort identification of pathology-proven cases of well-differentiated liposarcomas with myxoid stroma | University of Michigan |
| Aslam<sup>37</sup> | To review abdominopelvic and chest CT imaging reports for identifying the presence of metastatic disease and the sites of initial tumor and metastases when present | University of Michigan |
| Chappell<sup>38</sup> | Data abstraction for multiple transplantation-related variables, as well as disease and patient-specific data | University of Michigan |
| Manohar<sup>39</sup> | Data abstraction for demographic, clinical, staging, and pathologic data, among others; review of PET scan results | University of Michigan |

NOTE. References are shown with a brief description of how EMERSE was used based on the methods section of the articles. Abbreviations: CT, computed tomography; EMERSE, Electronic Medical Record Search Engine; FIGO, International Federation of Obstetrics and Gynecology; ICD-10, International Classification of Diseases, 10th edition; PET, positron emission tomography.
articles are provided in Table 2. The use of EMERSE varied from cohort identification to various types of data abstraction.

The audit logs revealed substantial use of EMERSE for cancer-related work that did not acknowledge EMERSE use within publications. This included multisite clinical trials where EMERSE was used at a single site (University of Michigan). These publications could be identified via unique data, such as National Clinical Trial numbers, which were sometimes mentioned in the publications. Examples include one study that used EMERSE for 31 sessions, with a total session time of 13 hours (ClinicalTrials.gov identifier: NCT01865747), another that used EMERSE for 58 sessions and 26 hours (ClinicalTrials.gov identifier: NCT01576172), and a third that used EMERSE for 398 user sessions and 166 hours (ClinicalTrials.gov identifier: NCT01633372).

Other oncology-related research initiatives have used EMERSE, even though it is not possible to link the use back to specific studies. For example, the Michigan Medicine Oncology Clinical Trials Support Unit has an umbrella institutional review board application for which it accesses EMERSE but does not link use to a specific study. That unit logged into EMERSE 917 times for 388 hours of use on the system between December 2014 and July 2019. Additionally, the Bone Marrow Transplant research group uses EMERSE for tracking long-term outcomes and used EMERSE for 2,452 sessions and 1,106 hours between July 2014 and July 2019. The high number of logins per study is common for research that involves frequent patient monitoring or identification of adverse events. Additional use statistics are listed in Table 1.

Details about the analysis of search terms using MetaMap are listed in Table 3. A large number of terms (University of Michigan, 34.1%; University of Cincinnati, 55.9%) did not map to any CUI using MetaMap. Many of these non-mapping terms were misspellings (eg, “fludaribine,” “ifosfomide,” “pegasparaganase,” “tamoxafen”). However, of the terms that did not map from the University of Michigan data set, 2,342 (9.0%) were numbers in various forms representing medical record numbers, dates, international classification of disease (ICD) codes, and even pathology slide identifiers. In the University of Cincinnati data set, 1,975 (68.6%) of the terms that did not map were numbers. The relative frequency of the 20 most common semantic types for the search terms is shown in Figure 3. “Disease or syndrome” was the most frequent semantic type (11.5%), followed by “pharmacologic substance” (10.0%).

**DISCUSSION**

As shown by the audit logs, and as evidenced by numerous peer-reviewed publications (> 100 oncology related), EMERSE has proven to be a useful tool for supporting cancer research. Furthermore, EMERSE has been successfully deployed at three academic medical centers to date, including the University of North Carolina, with additional centers in process, leading to multiple peer-reviewed publications.

Through several rounds of implementation work with other sites (several are still under way), we have learned a great deal about the complexities of enterprise-wide software implementation. We describe a few of the most important insights, provided as guidance for others who might be interested in implementing EMERSE or other centrally managed research tools.

Environments at each site are highly variable, including servers, storage, access to EHR documents, formats of these documents, and regulatory requirements. Although there is no cost per se for the software, the resources needed for implementation are not free. Competing priorities, institutional review board requirements, small teams, security reviews, and the need to obtain buy-in from leadership can delay implementation for months. There is no single solution to overcoming these challenges, but we have made efforts to reduce the burden on implementing sites, including providing installation and setup documentation, training materials for end users, and a messaging forum for technical teams.

Because EMERSE is meant to be user facing, preserving the original document formatting helps users understand the data in the notes. Modern EHRs, such as Epic, allow for documentation using rich text formatting, in which notes can be made with tables, line breaks, and other formatting (eg, bold-face text). However, the Epic analytics database, Clarity, almost universally stores a version of the notes stripped of all formatting. The University of North Carolina at Chapel Hill has avoided using Clarity and is using the live production database, Chronicles, instead.

**TABLE 3.** Results of MetaMap Search Terms Mapping and Total No. of Distinct Terms Entered at Each Site

| Institution                        | Distinct Search Terms | Terms That Did Not Map | Unique CUIs Mapped | Unique Semantic Types a |
|-----------------------------------|-----------------------|------------------------|--------------------|-------------------------|
| University of Michigan            | 76,540                | 26,098 (34.1%)         | 18,184             | 120                     |
| University of North Carolina at Chapel Hill | 2,855               | NA b                   | NA a               | NA b                    |
| University of Cincinnati          | 5,151                 | 2,881 (55.9%)          | 1,281              | 88                      |

Abbreviations: CUI, concept unique identifier; NA, not applicable.

a Of 127 possible semantic types. The full list of semantic types can be found online.

b Raw data not available for analysis.
The University of Utah, one of our partners, is working on a solution based on application program interfaces compliant with the Health Level Seven Fast Healthcare Interoperability Resources standard that should solve this challenge by extracting formatted notes in bulk. This approach is aligned with priorities of the US National Institutes of Health to "explore the use of the Fast Healthcare Interoperability Resources (FHIR) standard to capture, integrate, and exchange clinical data for research purposes and to enhance capabilities to share research data,\textsuperscript{27(p1)}"

Other sites, such as University of Cincinnati, have used simple logic and regular expressions to rebuild functional formatting in the notes. Contrary to when EMERSE was first developed and deployed, security considerations are becoming a top priority, as they are for any software that contains protected health information within a medical center. This focus on security requires substantial, ongoing resources for conducting repeated scans for vulnerabilities that exist in the underlying open-source components, as well as in the system configuration, code reviews, penetration testing, and other measures. This work adds to the development costs but is a necessary component that other sites are requiring before considering a deployment. The importance of software security, as well as local institutional policies, should not be underestimated.

Finally, demonstrating the value, effectiveness, and return on investment of software such as EMERSE remains challenging, especially if one considers peer-reviewed publications to be the gold standard of evidence. As demonstrated by the number of times the tool was used but never cited or mentioned, referencing software tools are not a top priority for many in the research community. However, this type of attribution is important to ensure future funding for software development teams, which can be expensive.

For the analysis of semantic types, it is worth noting that only a few of the semantic types identified are for data typically found in the structured section of EHRs (e.g., diseases, pharmaceutical substances). Many of the other concepts are likely to be found only in the free-text notes. Furthermore, many of the terms entered by users were not mappable by the popular NLP tool MetaMap. This could be because of limitations of current NLP tools or because users of EMERSE are searching for concepts that do not have a matching CUI or semantic type within UMLS.

The performance of MetaMap in our case likely could have been improved by adding an additional preprocessing step wherein incorrectly spelled terms would be mapped back to their correct spellings. Even though signs and symptoms are almost exclusively noted in the narrative portion of the medical record, these did not represent the most frequent semantic type. However, this may be because our analysis...
was performed on a unique list of terms in the search logs, and there may be far fewer signs and symptoms than there are disease or drug names.

Additional work under way involves securely networking sites for obfuscated counts. This feature will be similar to other cohort discovery networks currently based on structured data, such as i2b2 ACT\textsuperscript{28} and PCORnet,\textsuperscript{29} but the novelty with the EMERSE-based network is the focus on free-text notes. This should be useful for finding rare cancer cases where structured data are not specific enough. For example, there is no specific code in the ICD (version 10) for endometrial stromal sarcoma, because the parent code C54.1 represents multiple types of endometrial neoplasms.

It is important to point out that EMERSE is not meant to be a replacement for NLP systems, and NLP will be a preferable option in certain use cases. For relatively small numbers of patients (eg, thousands) and where accuracy is important enough to warrant human review, EMERSE may be the tool of choice. In other situations, such as automatically coding data across hundreds of thousands or millions of patients, NLP may be a preferable option. There is no one-size-fits-all solution, and multiple tools can benefit the research enterprise.

In conclusion, EMERSE can be a valuable tool to support cancer research as well as other clinical domains. This is a simple-to-operate, self-service tool that is powerful, scalable, and generalizable across use cases, allowing for teams from various fields to increase their productivity and gain access to accurate patient data that normally would have required a manual approach for identification. In addition, it has many data security features. Successful implementation at other locations has demonstrated that EMERSE can be deployed and used outside its original site. Groups interested in adopting EMERSE can contact the EMERSE team at the University of Michigan for a working virtual machine for testing, demonstrations, advice, and other details.

**AFFILIATIONS**

\textsuperscript{1}Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI

\textsuperscript{2}Case Western Reserve University School of Medicine, Cleveland, OH

\textsuperscript{3}University Hospitals of Cleveland, Cleveland, OH

\textsuperscript{4}Cleveland Institute for Computational Biology, Cleveland, OH

\textsuperscript{5}Department of Biomedical Informatics, University of Utah, Salt Lake City, UT

\textsuperscript{6}Markey Cancer Center, UK HealthCare, Lexington, KY

\textsuperscript{7}Division of Biomedical Informatics, University of Kentucky, Lexington, KY

\textsuperscript{8}Clinical and Translational Science Institute, University of California San Francisco, San Francisco, CA

\textsuperscript{9}Department of Biomedical Informatics, University of Cincinnati College of Medicine, Cincinnati, OH

\textsuperscript{10}Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY

\textsuperscript{11}North Carolina Translational and Clinical Sciences Institute, University of North Carolina School of Medicine, Chapel Hill, NC

\textsuperscript{12}Department of Informatics, University of California, Irvine, Irvine, CA

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**CORRESPONDING AUTHOR**

David A. Hanauer, 100-134 NCRC, 2800 Plymouth Rd, Ann Arbor, MI 48109; e-mail: hanauer@umich.edu.

**SUPPORT**

Supported in part by National Cancer Institute (NCI) Informatics Technology for Cancer Research, National Institutes of Health (NIH), Grant No. 1U24CA204863-01A1 and Clinical and Translational Science Award (CTSA)–supported Michigan Institute for Clinical and Translational Research Grant No. UL1TR002240; by the Cleveland Institute for Computational Biology and the Clinical and Translational Science Collaborative (CTSC) of Cleveland, funded by NIH National Center for Advancing Translational Science (NCATS) CTSA Grant No. UL1TR002548; by the North Carolina Translational and Clinical Sciences Institute, funded by NIH NCATS Grant No. UL1TR002489; and by the Markey Cancer Center Cancer Research Informatics Shared Resource Facility through NCI Cancer Center Support Grant No. P30CA177557.

**AUTHOR CONTRIBUTIONS**

Conception and design: David A. Hanauer, Mark F. Beno, Daniel Harris, Benjamin May, Kai Zheng

Administrative support: Eric Meeks

Provision of study material or patients: Eric B. Durbin, Oksana Gologorskaya

Collection and assembly of data: David A. Hanauer, Eric B. Durbin, Oksana Gologorskaya, Brett Harnett, Eric Meeks, Emily Pfaff

Data analysis and interpretation: David A. Hanauer, Jill S. Barnholtz-Sloan, Guilherme Del Fiol, Eric B. Durbin, Kensaku Kawamoto, Eric Meeks, Janie Weiss

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cc/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

David A. Hanauer

Patents, Royalties, Other Intellectual Property: Creator of a large database of clinical synonyms that can be used for query expansion, licensed by the University of Michigan Office of Technology Transfer and available for academic and nonacademic use (currently only licensed for academic use)
REFERENCES

1. Murdoch TB, Detsky AS: The inevitable application of big data to health care. JAMA 309:1351-1352, 2013
2. Polanshek B, Gilmore-Bykovskyi A, Hovanes M, et al: Overcoming the challenges of unstructured data in multisite, electronic medical record-based abstraction. Med Care 54:e65-e72, 2016
3. Kharrazi H, Anzaldi LJ, Hernandez L, et al: The value of unstructured electronic health record data in geriatric syndrome case identification. J Am Geriatr Soc 66:1499-1507, 2018
4. Hernandez-Boussard T, Tamang S, Blayney D, et al: New paradigms for patient-centered outcomes research in electronic medical records: An example of detecting urinary incontinence following prostatectomy. EGEMS (Wash DC) 4:1231, 2016
5. Zhang Y, Staley SA, Tucker K, et al: Malignant Brenner tumor of the ovary: Case series and review of treatment strategies. Gynecol Oncol Rep 28:29-32, 2019
6. Visweswaran S, Becich MJ, Dohan E, et al: Overcoming the challenges of unstructured data in multisite, electronic medical record-based abstraction. J Am Med Inform Assoc 24:986-991, 2017
7. Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814-1823, 2015
8. Warner JL, Levy MA, Neuss MN, et al: ReCAP: Feasibility and accuracy of extracting cancer stage information from narrative electronic health record data. J Oncol Pract 12:157-158, e169-e7, 2016
9. Savova GK, Danciu I, Alamudun F, et al: Use of natural language processing to extract clinician cancer phenotypes from electronic medical records. Cancer Res 79:5463-5470, 2019
10. Warner JL, Levy MA, Neuss MN, et al: ReCAP: Feasibility and accuracy of extracting cancer stage information from narrative electronic health record data. J Oncol Pract 12:157-158, e169-e7, 2016
11. Savova GK, Danciu I, Alamudun F, et al: Use of natural language processing to extract clinician cancer phenotypes from electronic medical records. Cancer Res 79:5463-5470, 2019
12. Carrell DS, Schoen RE, Leffler DA, et al: Challenges in adapting existing clinical natural language processing systems to multiple, diverse health care settings. J Am Med Inform Assoc 24:986-991, 2017
13. Kreimeyer K, Foster M, Pandey A, et al: Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review. J Biomed Inform 73:14-29, 2017
14. Gorski D: IBM Watson: Not living up to hype as a tool to fight cancer? https://scienceblogs.com/insolence/2017/09/18/ibm-watson-not-living-up-to-hype-as-a-tool-to-fight-cancer
15. Hanaauer DA, Mei Q, Law J, et al: Supporting information retrieval from electronic health records: A report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 55:290-300, 2015
16. EMERSE: Electronic Medical Record Search Engine. http://project-emense.org
17. Johnson AEW, Pollard TJ, Shen L, et al: MIMIC-III, a freely accessible critical care database. Sci Data 3:160035, 2016
18. MetaMap: A tool for recognizing UMLS concepts in text. https://metamap.nlm.nih.gov
19. RealEgur R, Rahet S: Comparison of MetaMap and cTAKES for entity extraction in clinical notes. BMC Med Inform Decis Mak 18:74, 2018 (suppl 3)
20. Wu ST, Liu H, Li D, et al: Unified Medical Language System term occurrences in clinical notes: A large-scale corpus analysis. J Am Med Inform Assoc 19(e1): e149-e156, 2012
21. Mazioli M, Elli L, Caviglia G, et al: TARGET: A visualisation platform to create open outputs. Presented at the 12 Biannual Conference of the Italian SIGCHI Chapter, Cagliari, Italy, September 18-20, 2017
22. Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814-1823, 2015
23. Hussain M, Daignault-Newton S, Twardowski PW, et al: Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results of phase II open-label trial of INCBO39110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica 102:327-335, 2017
24. Emecoff NC, Wessell KL, Hanson LC, et al: Electronic health record phenotypes for identifying patients with late-stage disease: A method for research and clinical application. J Gen Intern Med 34:2818-2823, 2019
25. Bender D, Sartipi K: HL7 FHIR: An Agile and RESTful approach to healthcare information exchange. Presented at the 26 IEEE International Symposium on Computer-Based Medical Systems, Porto, Portugal, June 20-22, 2013
26. National Institutes of Health Office of Data Science Strategy: Fast Healthcare Interoperability Resources (FHIR) standard. https://datascience.nih.gov/foa/fast-healthcare-interoperability-resources-fhir-standard
27. Polanshek B, Gilmore-Bykovskyi A, Hovanes M, et al: Overcoming the challenges of unstructured data in multisite, electronic medical record-based abstraction. Med Care 54:e65-e72, 2016
28. Visweswaran S, Becich MJ, Dohan E, et al: Overcoming the challenges of unstructured data in multisite, electronic medical record-based abstraction. J Am Med Inform Assoc 24:986-991, 2017
29. Fleurence RL, Curtis LH, Califf RM, et al: Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc 21:578-582, 2014
30. Zhang Y, Staley SA, Tucker K, et al: Malignant Brenner tumor of the ovary: Case series and review of treatment strategies. Gynecol Oncol Rep 28:29-32, 2019

Eric Meeks
Stock and Other Ownership Interests: WestPac Wealth Partners
No other potential conflicts of interest were reported.
31. Tsao PA, Estes JP, Griggs JJ, et al: Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: Post-marketing experience. Clin Genitourin Cancer 17:e592-e601, 2019
32. Siontis BL, Zhao L, Leja M, et al: Primary cardiac sarcoma: A rare, aggressive malignancy with a high propensity for brain metastases. Sarcoma 2019:1960593, 2019
33. Lazo de la Vega L, Samaha MC, Hu K, et al: Multiclonality and marked branched evolution of low-grade endometrioid endometrial carcinoma. Mol Cancer Res 17:731-740, 2019
34. Shankar PR, Barkmeier D, Hadjiiski L, et al: A pictorial review of bladder cancer nodal metastases. Transl Androl Urol 7:804-813, 2018
35. Hertz DL, Glatz A, Pasternak AL, et al: Integration of germline pharmacogenetics into a tumor sequencing program. JCO Precis Oncol 10.1200/PO.18.00011
36. Morag Y, Yablon C, Brigidio MK, et al: Imaging appearance of well-differentiated liposarcomas with myxoid stroma. Skeletal Radiol 47:1371-1382, 2018
37. Asham A, Mendiratta-Lala M, Curci ME, et al: Role of pelvic CT during surveillance of patients with resected biliary tract cancer. Abdom Radiol (NY) 45:116-122, 2020
38. Chappell G, Geer M, Gatza E, et al: Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplant 54:1518-1520, 2019
39. Manohar PM, Beesley LJ, Bellile EL, et al: Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clin Nucl Med 43:641-647, 2018
40. MetaMap: List of semantic types. https://metamap.nlm.nih.gov/Docs/SemanticTypes_2018AB.txt